Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Synthetic Drug Control Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · second_quarter · 2A
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
Source: Senate LDA
Synthetic Drug Control Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Synthetic Drug Control Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
STEAM (Stripping The E-Prescribe Arbitrary Mandates) Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
STEAM (Stripping The E-Prescribe Arbitrary Mandates) Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
STEAM (Stripping The E-Prescribe Arbitrary Mandates) Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
Generating Antibiotic Incentives Now Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
Generating Antibiotic Incentives Now Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
Generating Antibiotic Incentives Now Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Generating Antibiotic Incentives Now Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Generating Antibiotic Incentives Now Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Generating Antibiotic Incentives Now Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Generating Antibiotic Incentives Now Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Medicare Drug Savings Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Medicare Drug Savings Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
Medicare Drug Savings Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
Medicare Drug Savings Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Medicare Drug Savings Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Safeguarding America's Pharmaceuticals Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Counterfeit Drug Penalty Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Counterfeit Drug Penalty Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Counterfeit Drug Penalty Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Counterfeit Drug Penalty Enhancement Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Counterfeit Drug Penalty Enhancement Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Counterfeit Drug Penalty Enhancement Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Counterfeit Drug Penalty Enhancement Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Shortage Prevention Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
BPCA and PREA Reauthorization Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
BPCA and PREA Reauthorization Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
BPCA and PREA Reauthorization Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
BPCA and PREA Reauthorization Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
BPCA and PREA Reauthorization Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
Patient Safety and Drug Labeling Improvement Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
Patient Safety and Drug Labeling Improvement Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
Medicare Decisions Accountability Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Medicare Decisions Accountability Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Medicare Decisions Accountability Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Medicare Decisions Accountability Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Medicare Decisions Accountability Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Medicare Decisions Accountability Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Food and Drug Administration Reform Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
Food and Drug Administration Reform Act of 2012
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
Synthetic Drug Control Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
Synthetic Drug Control Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
Synthetic Drug Control Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer
Drug Safety Enhancement Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
Generating Antibiotic Incentives Now Act of 2011
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
Issues related to implementation of US-Korea Free Trade Agreement Issues related to Non-tariff trade barriers in Turkey Issues related to US position on intellectual property matters in Canada
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · first_quarter · 1A
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
Issues related to US position on intellectual property matters in Canada Issues related to Non-tariff trade Barriers in Turkey
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · second_quarter · Q2
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
Issues related to implementation of US-Korea Free Trade Agreement Issues related to Non-tariff trade barriers in Turkey Issues related to US position on intellectual property matters in Canada
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · first_quarter · 1A
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
Issues related to US position on intellectual property matters in Canada Issues related to Non-tariff trade Barriers in Turkey
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · first_quarter · Q1
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Issues related to US position on intellectual property matters in Canada Issues related to Non-tariff trade Barriers in Turkey
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
H.R. 2245, S. 296, H.R. 3839 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · second_quarter · 2A
HR 5 (Help Efficient, Accessible, Low-cost Timely Healthcare Act of 2011) - issues related medical malpractice reform HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to development of antibiotics
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilizationS. 1251 - issues related to Medicare fraud and abuse laws HR 2190, S. 1206 - issues related to Medicare Part D rebates HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152), HR 2248 - issues related to health care reform legislation and implementation, including proposed changes to the Medicare Program regarding pharmaceutical rebates and price negotiation
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · fourth_quarter · 4A
Issues related to US position on intellectual property protections offered by US in international trade treaty
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · third_quarter · 3A
HR 2112, HR 2190, S1206 - Proposed legislation regarding FDA appropriations FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · fourth_quarter · Q4
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · third_quarter · Q3
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · third_quarter · Q3
HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer
HR 2112, HR 2190, S1206 - Proposed legislation regarding FDA appropriations FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · second_quarter · 2A
S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issuess related to the development of antibiotics Participate in executive branch discussions regarding intellectual property issues arising in foreign countries Discussions regarding global/free trade agreements and protection of intellectual property
HR 5 (Help Efficient, Accessible, Low-cost Timely Healthcare Act of 2011) - issues related medical malpractice reform HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to development of antibiotics
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · first_quarter · 1A
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, State, Dept of (DOS)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · second_quarter · Q2
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization S. 1251 - issues related to Medicare fraud and abuse laws HR 2190, S. 1206 - issues related to Medicare Part D rebates HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152), HR 2248 - issues related to health care reform legislation and implementation, including proposed changes to the Medicare Program regarding pharmaceutical rebates and price negotiation
S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issuess related to the development of antibiotics Participate in executive branch discussions regarding intellectual property issues arising in foreign countries Discussions regarding global/free trade agreements and protection of intellectual property
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · first_quarter · Q1
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) HR 6331 - issues related to legislation regarding development of antibiotics HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including transparency ("Sunshine") reporting requirements 340B Drug Pricing program issues, including expansion of eligible entities and impacts of health care reform changes
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, State, Dept of (DOS)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · fourth_quarter · 4A
S. 3677, HR 4899 - legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Participate in executive branch discussions regarding intellectual property issues arising in foreign countries
HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to healthcare reform legislation and implementation, including the newly-created Independent Payment Advisory Board, evidence-based medicine, and health information technology HR 6331 - issues related to antibiotic development legislation Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) Monitoring implementation of existing legislative and regulatory proposals and possible future legislative developments regarding Health Information Technology and Personal Health Records (unassigned) Participate in executive branch discussions regarding pharmaceutical pricing and reimbursement regimes in foreign countries
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · fourth_quarter · Q4
FDA Appropriations issues, including issues likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (currently unassigned) General FDA Issues
HR 3590, S 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to healthcare reform legislation and implementation, including the newly-created Independent Payment Advisory Board, evidence-based medicine, and health information technology HR 6331 - issues related to antibiotic development legislation Monitoring and discussing issues under discussion by the President's Deficit Commission, including recommendations regarding the Independent Payment Advisory Board and Medicare Part D rebates (unassigned) Monitoring implementation of existing legislative and regulatory proposals and possible future legislative developments regarding Health Information Technology and Personal Health Records (unassigned) Participate in executive branch discussions regarding pharmaceutical pricing and reimbursement regimes in foreign countries
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · third_quarter · Q3
S. 3677, HR 4899 - legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Patent issues associated with anti-biotics (currently unassigned)
HR 5175, S 3295, S 3628 - legislative proposals related to campaign finance issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · second_quarter · 2A
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
H.R. 3590, S.1796 and related bills and amendments - legislative and regulatory proposals surrounding health care, including provisions regarding Medicaid rebates and patient savings in Medicare Part D coverage gap
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · second_quarter · Q2
FDA funding and appropriation issues (PDUFA V) (currently unassigned)
H.R.9175 and related bills and amendments - legislative proposals surrounding political action committee issues
H.R. 3590, S.1796 and related bills and amendments - legislative and regulatory proposals surrounding health care, including provisions regarding Medicaid rebates and patient savings in Medicare Part D coverage gap
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2010 · first_quarter · Q1
HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding Patent reform and intellectual property issues, including issues surrounding patent settlements HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding follow-on biologics/pathway for biosimilar pharmaceuticals
HR. 3590, S 1796 and related bills and amendments - legislative proposals surrounding health care reform including provisions regarding pharmaceutical pricing and proposed revisions to 340B program FDA appropriations issues (currently unassigned)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · fourth_quarter · Q4
HR 3590, S 1796, and related bills and amendments - Proposed revisions to 340B program HR 3590, S 1796, and related bills and amendments - Legislative proposals surrounding health care reform, including provisions regarding pharmaceutical pricing, insurance reform, and reimbursement issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · third_quarter · Q3
Health Reform S.301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Independent Drug Education and Outreach Act - Academic Detailing Issues Veterans Health Care Budget Reform and Transparency Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · first_quarter · 1A
Medicaid - regarding possible increase in Medicaid base rebate; other issues regarding possible changes to Medicaid rebate program Comparative Effectiveness - regarding use of Comparative effectiveness in health care coverage and/or reimbursement Medicare - regarding "non-interfence" clause, protected classed of drugs, and Medicare Advantage
Health Care Reform S. 301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Mental Health Parity 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services VA/DoD Tricare - regarding TRICARE retail rebate legislation/rulemaking Discussions regarding global access to medicines Legislation or possible legislation regarind stem cell research Discussions regarding possible opportunities to work with CMS on education and outreach efforts
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · second_quarter · Q2
Health Care Reform S.301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Discuss Patient Assistance Programs Issues regarding disclosure of drug sample data Independent Drug Education and Outreach Act - Academic Detailing issues VA/DoD regarding TRICARE retail rebate legislation Veterans Health Care Budget Reform and Transparency Act Discussions regarding global access to medicines
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2009 · first_quarter · Q1
Health Care Reform S. 301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Mental Health Parity 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services VA/DoD Tricare - regarding TRICARE retail rebate legislation/rulemaking Discussions regarding global access to medicines Legislation or possible legislation regarind stem cell research Discussions regarding possible opportunities to work with CMS on education and outreach efforts
Patent Reform and intellectual property issues Section 182 ("Special 301") briefings on global intellectual property protections Discussions regarding patent settlements (reverse payments) legislation Discussions regarding follow on biologics
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · third_quarter · 3A
Discussions regarding protection of patient safety from the commercial importation of prescription medications Discussions regarding impact and safety issues surrounding the presence of pharmaceuticals in the environment - No specific legislation HR 5839-The Safeguarding America's Pharmaceuticals Act-US House Import Safety Discussion Draft legislation-US House/US Senate
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Discussions regarding intellectual property issues with Members and Staff-US House Discussions regarding authorized generics legislation-US House/US Senate Discussions regarding Patent Settlements (reverse payments) Legislation-US House/US Senate
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · fourth_quarter · Q4
Medcaid Base Rebate Increase-US House Medicare:S.3101/H.R. 6331-The Medicare Improvements for Patients & Providers Act S.3118-The Preserving Access to Medicare Act Waxman proposal for Medicaid-type rebates for dual elibigles enrolled in Medicare Part D. No active legislation-US House Discussions regarding maintenance of six protected classes of pharmaceutical products under Medicare Part D Anti-Preemption Medicare Part D-US House
S.558-The Mental Health Parity Act Comparative Effectiveness Research - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement Health Care Reform:S.334-The Healthy Americans Act H.R. 1424-The Paul Wellstone Mental Health and Addiction Equity Act Cancer access and affordability issues, generally. No active legislation. Provision of information regarding company patient assistance programs. No active legislation. HIT 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services Grassley/Kohn Physician Payments Sunshine Act Minority Outreach - Congressional Hispanic Caucus. No active legislation.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · third_quarter · Q3
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Discussions regarding intellectual property issues with Members and Staff-US House Discussions regarding authorized generics legislation-US House/US Senate Discussions regarding Patent Settlements (reverse payments) Legislation-US House/US Senate
S.558-The Mental Health Parity Act H.R. 1424-The Paul Wellstone Mental Health and Addiction Equity Act Health Care Reform:S.334-The Healthy Americans Act Cancer access and affordability issues, generally. No active legislation. Grassley/Kohl Physician Payments Sunshine Act Comparative Effectiveness Research - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services Minority Outreach - Congressional Hispanic Caucus. No active legislation Provision of information regarding company patient assistance programs. No active legislation
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · second_quarter · Q2
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage S.2029 - Physician Payments Sunshine Act of 2007; Grassley/Kohl Bill - regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis DoD Tricare issues, including retail pharmacy rebate and other issues Comparative Effectivensss - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement Genetic Information Nondiscrimination Act Information regarding company patient assistance program Health care reform Legislation to fund cancer research, cancer supportive services and improve access to coverage 340B program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
FDA appropriations Support of sufficient funding for the Food & Drug Administration to conduct meaningful and effective review of direct-to-consumer advertising
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · first_quarter · 1A
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2008 · first_quarter · Q1
S.1145, The Patent Reform Act of 2007, Potenital implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries Intellectual property provisions of Free-Trade Agreements and otherwise as part of US trade policy HR 1432, HR 1902 - Patent Settlement Bills re: prohibition of brand name manufacturers compensating generic manufacturers for delay of generic entry to market HR 5629, H.R. 1956, H.R. 1038, S. 1695 Pathway for Biosimilars Act, U.S. House - legislation regarding patent protection of biological products re: generic/follow-on biologic products
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate General discussion and increasing awareness of patient assistance program offerings Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and MedicareAdvantage H.R. 3162 - Children's Health and Medicare Protection Act of 2007 - regarding Medicare Physician Reimbursement Package, Medicare and Medicaid Drug Reimbursement
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2007 · year_end · YY
S.1082 FDARA - reauthorization and funding of FDA and PDUFA-related issues HR 2900 FDAAA - reauthorization and funding of FDA and PDUFA-related issues HR 3610 Food & Drug Safety Act of 2007 - reauthorization and funding of FDA and PDUFA-related issues S. 1859/HR 3161 - Ag, Rural Dev, FDAdministration & Related Agencies Approp Act of 2008 - reauth and funding of FDA
Proposed increase in Medicaid Drug Rebate drug base rebate increase Proposed changes to Medicaid price reporting and requirements from earlier legislation (DRA) Medicare Part D formulary protection for six specified classes
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2007 · mid_year · MM
S.5 & H.R. 3 - Stem Cell Research Enhancement Act of 2007
S.3 - Medicare Prescription Drug Price Negotiation Act of 2007 H.R. 4 - Medicare Prescription Drug Price Negotiation Act of 2007 Medicaid Rebate Rate
Drug Importation Issues S.A. 1010 - Safety and Cost Savings Certification re: Importation of Pharmaceuticals S. 242 & H.R.380 - Pharmaceutical Market Access and Drug Safety Act of 2007 Safe Drug Compounding Act of 2007 (draft legislation - no bill number)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2005 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2004 · year_end · YY
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issuesHR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issuess related to the development of antibiotics Participate in executive branch discussions regarding intellectual property issues arising in foreign countries Discussions regarding global/free trade agreements and protection of intellectual property
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet) HR 2112, HR 2190, S1206 - Proposed legisalation regarding FDA appropriations
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)
Discussions regarding possible clarifications to labor rules, including wage and hour issues
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Discussions regarding possible clarifications to labor rules, including wage and hour issues
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues. Discussions regarding global/free trade agreements and protection of intellectual property
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
HR 1483, S.1584 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)
Issues related to US position on intellectual property protections offered by US in international trade treaty
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
Discussions regarding possible clarifications to labor rules, including wage and hour issues
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)
Issues related to US position on intellectual property protections offered by US in international trade treaty
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
Discussions regarding possible clarifications to labor rules, including wage and hour issues
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)
Discussions regarding possible clarifications to labor rules, including wage and hour issues
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements S. 23, HR 1249 (America Invents Act) - legislative proposals regarding patent reform including "first to file" and "supplemental re-examination" issues. Discussions regarding global/free trade agreements and protection of intellectual property
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet) HR 2112, HR 2190, S1206 - Proposed legisalation regarding FDA appropriations
HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicare Part D Coverage Gap Program HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization S. 1251 - issues related to Medicare fraud and abuse laws HR 2190, S. 1206 - issues related to Medicare Part D rebates HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform legislation and implementation, including the newly-created Independent Payment Advisory Board HR 3590, S. 1790, HR 4872 (as enacted into PL 111-148 and PL 111-152), HR 2248 - issues related to health care reform legislation and implementation, including proposed changes to the Medicare Program regarding pharmaceutical rebates and price negotiation
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
HR 5 (Help Efficient, Accessible, Low-cost Timely Healthcare Act of 2011) - issues related medical malpractice reform HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to development of antibiotics
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (no bill number yet) HR 2112, HR 2190, S1206 - Proposed legisalation regarding FDA appropriations
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
FDA Appropriations issues, including issues likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) V (currently unassigned) General FDA Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)
S. 3677, HR 4899 - legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Participate in executive branch discussions regarding intellectual property issues arising in foreign countries
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)
H.R.3590, S.1796 and related bills and amendments - legislative and regulatory proposals surrounding health care reform, including provisions regarding pharmaceutical pricing H.R. 4213 and related bills and amendments - proposals surrounding 340B program
H.R.9175 and related bills and amendments - legislative proposals surrounding political action committee issues
FDA funding and appropriation issues (PDUFA V) (currently unassigned)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R.3590, S.1796 and related bills and amendments - legislative and regulatory proposals surrounding health care reform, including provisions regarding pharmaceutical pricing H.R. 4213 and related bills and amendments - proposals surrounding 340B program
H.R.3590, S.1796 and related bills and amendments - legislative proposals surrounding health care reform, including provisions regarding patent reform and intellectual property issues, including patent setttlements H.R.4899 and related bills and amendments - legislative proposals surrounding patent reform and intellectual property issues, including patent setttlements
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Patent Reform and intellectual property issues Section 182 ("Special 301") briefings on global intellectual property protections Discussions regarding patent settlements (reverse payments) legislation Discussions regarding follow on biologics
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Medicaid - regarding possible increase in Medicaid base rebate; other issues regarding possible changes to Medicaid rebate program Comparative Effectiveness - regarding use of Comparative effectiveness in health care coverage and/or reimbursement Medicare - regarding "non-interfence" clause, protected classed of drugs, and Medicare Advantage
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Discussions regarding FDA Appropriations Discussions regarding e-Prescribing Discussions regarding implementation of PDUFA IV/FDAAA Direct-to-Consumer Advertisement User Fee Program
S.558-The Mental Health Parity Act H.R. 1424-The Paul Wellstone Mental Health and Addiction Equity Act Health Care Reform:S.334-The Healthy Americans Act Cancer access and affordability issues, generally. No active legislation. Grassley/Kohl Physician Payments Sunshine Act Comparative Effectiveness Research - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services Minority Outreach - Congressional Hispanic Caucus. No active legislation Provision of information regarding company patient assistance programs. No active legislation
Medicaid Base Rebate Increase-US House Medicare:S.3101/H.R. 6331-The Medicare Improvements for Patients & Providers Act; S.3118-The Preserving Access to Medicare Act; Deficit Reduction Act-US Senate Waxman proposal for Medicaid-type rebates for dual eligibles enrolled in Medicare Part D. No active legislation-US House Discussions regarding retaining private market price negotiations between manufacturers and Medicare Part D plans -US Senate Discucssions with the Office of Provider Relations, CMS Discussions regarding maintenance of six protected classes of pharmaceutical products under Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
S.1145-The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencis that do not harm innovative industries-US Senate Patent settlements (reverse payments) legislation-US House/US Senate Regarding intellectual property issues
Import Safety Discussion Draft Legislation-US House/US Senate FDA Import Safety/FDA Globalization Act Discussions regarding protection of patient safety from the commercial importation of prescription medications HR 5839-The Safeguarding America's Pharmaceuticals Act-US House Discussions regarding impact and safety issues surrounding the presence of pharmaceuticals in the environment. No specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Discussions regarding FDA Appropriations Discussions regarding e-Prescribing Discussions regarding implementation of PDUFA IV/FDAAA Direct-to-Consumer Advertisement User Fee Program
Discussions regarding protection of patient safety from the commercial importation of prescription medications Discussions regarding impact and safety issues surrounding the presence of pharmaceuticals in the environment - No specific legislation HR 5839-The Safeguarding America's Pharmaceuticals Act-US House Import Safety Discussion Draft legislation-US House/US Senate
Medicaid Base Rebate Increase-US House Medicare:S.3101/H.R. 6331-The Medicare Improvements for Patients & Providers Act; S.3118-The Preserving Access to Medicare Act; Deficit Reduction Act-US Senate Waxman proposal for Medicaid-type rebates for dual eligibles enrolled in Medicare Part D. No active legislation-US House Discussions regarding retaining private market price negotiations between manufacturers and Medicare Part D plans -US Senate Discucssions with the Office of Provider Relations, CMS Discussions regarding maintenance of six protected classes of pharmaceutical products under Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
S.1145, The Patent Reform Act of 2007, Potential implications of pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries HR 5629, Pathway for Biosimilars Act Intellectual property provisions of free-trade agreements and otherwise as part of US trade policy
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate Issues arising from Deficit Reduction Act Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage S.3101 & H.R. 6331 - The Medicare Improvements for Patients & Providers Act S.3118 - The Preserving Access to Medicare Act Legislation to address physician payment issues, including SGR, and related provisions to Medicare package
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate General discussion and increasing awareness of patient assistance program offerings Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and MedicareAdvantage
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office
S.558 & H.R. 1424 - The Mental Health Parity Act of 2007 - regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage Physician Payments Transparency - Grassley/Kohl Bill - regarding proposal to require pharmaceuctical manufacturers to disclose provision of items of value to physicians on an annual basis Legislation to fund cancer research, cancer supportive services, and improve access to coverage S.329 Pulmonary and Cardiac Rehabilitation Act of 2007 - regarding possible amendments to Title XVIII of SSA to provide coverage of items and services under cardiac or pulmonary rehabilitation programs Comparative Effectiveness - Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office
Renewal of Research and Development Tax Credit within context of proposed changes to Alternative Minimum Tax
S.1145/1908 The Patent Reform Act of 2007 - Potential implications on pharmaceutical patent protection, including reform to address current inefficiencies that do not harm innovative industries
Patient safety from the commercial importation of prescription medications Manufacturer outsourcing of active pharmaceutical ingredients to certain countries
Illegal compounding of commercially available pharmaceuticals by pharmacists
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.1082-Food and Drug Administration Revitalization Act of 2007 H.R. 2900 Food and Drug Administration Amendments Act of 2007 Illegal Pharmaceutical Manufacturing S.1859 Agriculture Appropriations - Title VI: Food and Drug Administration
S. 316 & H.R. 1432 - Preserve Access to Affordable Generics Act H.R. 1902 - Protecting Access to Generic Drugs Act of 2007 H.R. 1908-Patent Reform Act of 2007 H.R. 1038-Access to Life-Saving Medicine Act - Follow-on Biologics H.R. 1956-Patient Protection and Innovative Biologic Medicines Act of 2007 S.1145-Patent Reform Act of 2007
H.R. 1424 The Paul Wellstone Mental Health and Addiction Equity Act of 2007 S. 1893-Children's Health Insurance Program Reauthorization Act H.R. 3162-Children's Health Insurance Program Reauthorization Act S.558-The Mental Health Parity Act of 2007 S. 1376 - 340B Program Improvement and Integrity Act of 2007
Filing targets: HOUSE OF REPRESENTATIVES, SENATE